Are Medical Stocks Lagging DURECT (DRRX) This Year?
H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating
H.C. Wainwright analyst Ed Arce maintains $Durect(DRRX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of 8.6% over the past year
Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5
Northland Securities analyst Carl Byrnes maintains $Durect(DRRX.US)$ with a buy rating, and maintains the target price at $8.5.According to TipRanks data, the analyst has a success rate of 37.0% and a
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago
Express News | Hearing Oppenheimer Reiterates Outperform And $5 PT On DURECT
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon
Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I
DURECT Gets FDA Breakthrough Therapy Status for Larsucosterol
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR
Express News | DURECT Corp -DURECT Plans to Confirm Efficacy and Safety of Larsucosterol in a Registrational Phase 3 Clinical Trial
Express News | DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
Express News | HC Wainwright & Co. Reiterates Neutral on Durect
Durect Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 449.39% Oppenheimer → $5 Reiterates Outp
Durect | 10-Q: Quarterly report
Express News | DURECT Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q1 Revenue Results
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says
Durect (DRRX) is not yet an earnings story but recent feedback from the US Food and Drug Administration is encouraging over its support for the advancement of larsucosterol into a single late-stage tr
Cutera, Inotiv, Treace Medical Concepts Among Healthcare Movers
Durect (DRRX) Gets a Buy From Oppenheimer
Durect (DRRX) Receives a Hold From H.C. Wainwright
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...